Laurion Capital Management’s Pyxis Oncology PYXS Stock Holding History

Laurion Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.3M	Buy	4,997,333 +200,854	+4%	+$303K	0.32%	91
2025 Q4	$5.52M	Buy	4,796,479 +1,170,505	+32%	+$4.13M	0.21%	78
2025 Q3	$8.05M	Hold	3,625,974	–	–	0.14%	109
2025 Q2	$3.99M	Hold	3,625,974	–	–	0.07%	139
2025 Q1	$3.55M	Hold	3,625,974	–	–	0.09%	125
2024 Q4	$5.66M	Hold	3,625,974	–	–	0.1%	137
2024 Q3	$13.3M	Sell	3,625,974 -235,205	-6%	-$823K	0.18%	60
2024 Q2	$12.8M	Hold	3,861,179	–	–	0.15%	99
2024 Q1	$16.4M	Buy	3,861,179 +690,376	+22%	+$2.9M	0.14%	140
2023 Q4	$5.71M	Hold	3,170,803	–	–	0.05%	233
2023 Q3	$6.31M	Hold	3,170,803	–	–	0.04%	262
2023 Q2	$8.12M	Hold	3,170,803	–	–	0.05%	228
2023 Q1	$12.7M	Hold	3,170,803	–	–	0.09%	183
2022 Q4	$4.25M	Hold	3,170,803	–	–	0.02%	273
2022 Q3	$6.25M	Hold	3,170,803	–	–	0.04%	234
2022 Q2	$7.55M	Buy	3,170,803 +1,950,971	+160%	+$5.19M	0.12%	133
2022 Q1	$4.93M	Buy	1,219,832 +57,500	+5%	+$420K	0.06%	166
2021 Q4	$12.8M	Buy	+1,162,332	New	+$13.3M	0.13%	109

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

Laurion Capital Management's PYXS Position: Q1 2026 in Review

Laurion Capital Management increased its Pyxis Oncology (PYXS) stake by 4.2% in Q1 2026, buying an estimated $303K and bringing the position to 4,997,333 shares worth $7.3M. The position accounts for 0.32% of the portfolio, ranked #91.

Laurion Capital Management first reported a position in PYXS in Q4 2021 and has held it in 18 quarters since. The position peaked at $16.4M in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

Laurion Capital Management held 4,997,333 shares of Pyxis Oncology worth $7.3M as of Q1 2026.
Laurion Capital Management bought 200,854 Pyxis Oncology shares in Q1 2026, an estimated $303K.
Pyxis Oncology made up 0.32% of Laurion Capital Management's portfolio in Q1 2026, its #91 holding.
Laurion Capital Management first reported a position in Pyxis Oncology in Q4 2021 and has held it in 18 quarters since.
Laurion Capital Management's Pyxis Oncology position peaked at $16.4M in Q1 2024.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.